Cardiopulmonary Responses and Prognosis in Hypertrophic Cardiomyopathy

Finocchiaro, Gherardo; Haddad, François; Knowles, Joshua; Caleshu, Colleen; Pavlović, Aleksandra; Homburger, Julian R.; Shmargad, Yael; Sinagra, Gianfranco; Magavern, Emma; Wong, Myo; Pérez, Marco; Schnittger, Ingela; Myers, Jonathan; Froelicher, Victor; Ashley, Euan A.

doi:10.1016/j.jchf.2014.11.011

Cited by 80 publications

(60 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Smaller studies have yielded similar results. 43,44 These findings mirror the robust prognostic significance of peak VO 2 in the broader heart failure population. 45,46 Furthermore, peak VO 2 is sensitive to therapeutic interventions leading to symptomatic relief and increased functional capacity in patients with HCM, as shown by the significant increases observed after surgical myectomy 47 and percutaneous alcohol septal ablation.…”

Section: Rationale For Primary End Point: the Role Of Vo 2 Maxmentioning

confidence: 59%

Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy

Olivotto

Hellawell

Farzaneh‐Far

et al. 2016

Circ: Heart Failure

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Rationale For Primary End Point: the Role Of Vo 2 Maxmentioning

confidence: 59%

Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy

Olivotto

Hellawell

Farzaneh‐Far

et al. 2016

Circ: Heart Failure

Self Cite

View full text Add to dashboard Cite

show abstract

“…[86][87][88][89][90] More recent reports suggest that noninvasively determined peak cardiac index complements indexes of ventilatory inefficiency and peak V ⋅ o 2 and that combining these markers provides the most powerful stratification of risk. 91,92 Although the Fick and thermodilution methods remain the gold standards for the measurement of CO, 93 several rebreathing methods that use CPX are available. Bioelectric impedance has also experienced a renewed interest in recent years, and along with a number of validation studies, cardiac hemodynamics with these techniques have been shown to have prognostic value in patients with HF.…”

Section: Circulatory Powermentioning

confidence: 99%

2016 Focused Update: Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations

et al. 2016

Self Cite

View full text Add to dashboard Cite

Abstract-In the past several decades, cardiopulmonary exercise testing (CPX) has seen an exponential increase in its evidence base. The growing volume of evidence in support of CPX has precipitated the release of numerous scientific statements by societies and associations. In 2012, the European Association for Cardiovascular Prevention & Rehabilitation and the American Heart Association developed a joint document with the primary intent of redefining CPX analysis and reporting in a way that would streamline test interpretation and increase clinical application. Specifically, the 2012 joint scientific statement on CPX conceptualized an easy-to-use, clinically meaningful analysis based on evidence-vetted variables in color-coded algorithms; single-page algorithms were successfully developed for each proposed test indication. Because of an abundance of new CPX research in recent years and a reassessment of the current algorithms in light of the body of evidence, a focused update to the 2012 scientific statement is now warranted. The purposes of this update are to confirm algorithms included in the initial scientific statement not requiring revision, to propose revisions to algorithms included in the initial scientific statement, to propose new algorithms based on emerging scientific evidence, to further clarify the application of oxygen consumption at ventilatory threshold, to describe CPX variables with an emerging scientific evidence base, to describe the synergistic value of combining CPX with other assessments, to discuss personnel considerations for CPX laboratories, and to provide recommendations for future CPX research. (Circulation. 2016;133:e694-e711.

show abstract

“…HCM patients with paroxysmal AF show reduced exercise capacity and is associated with markedly increased risk of death by stroke and heart failure. 51 , 52 Moreover, AF is associated with advanced disease progression in HCM patients. 52 AF may be caused by atrial dilatation in response to diastolic ventricular dysfunction.…”

Section: Atrial Fibrillationmentioning

confidence: 99%

“… 51 , 52 Moreover, AF is associated with advanced disease progression in HCM patients. 52 AF may be caused by atrial dilatation in response to diastolic ventricular dysfunction. However, it may also involve a direct effect of the mutant protein on atrial myocyte function.…”

Section: Atrial Fibrillationmentioning

confidence: 99%

Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology

Velden

Tocchetti

Varricchi

et al. 2018

Cardiovascular Research

View full text Add to dashboard Cite

Disturbed metabolism as a consequence of obesity and diabetes may cause cardiac diseases (recently highlighted in the cardiovascular research spotlight issue on metabolic cardiomyopathies).1 In turn, the metabolism of the heart may also be disturbed in genetic and acquired forms of hypertrophic cardiac disease. Herein, we provide an overview of recent insights on metabolic changes in genetic hypertrophic cardiomyopathy and discuss several therapies, which may be explored to target disturbed metabolism and prevent onset of cardiac hypertrophy.This article is part of the Mini Review Series from the Varenna 2017 meeting of the Working Group of Myocardial Function of the European Society of Cardiology.

show abstract

Cardiopulmonary Responses and Prognosis in Hypertrophic Cardiomyopathy

Abstract: In HCM, peak cardiac index is the main determinant of exercise capacity, but it is not significantly related to ventilatory efficiency. Peak Vo2, ventilatory inefficiency, and LAVI are associated with an increased risk of major events in the short-term follow-up.

Cited by 80 publications

References 35 publications

Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy

Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy

2016 Focused Update: Clinical Recommendations for Cardiopulmonary Exercise Testing Data Assessment in Specific Patient Populations

Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology

Contact Info

Product

Resources

About